Format

Send to

Choose Destination
Br J Pharmacol. 2015 Sep;172(17):4228-37. doi: 10.1111/bph.13211. Epub 2015 Jul 30.

Therapeutic targets of triple-negative breast cancer: a review.

Author information

1
Laboratory of Molecular Pharmacology and Toxicology, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Gauhati Medical College, Guwahati, India.
2
Academy of Scientific and Innovative Research (AcSIR), New Delhi, India.
3
Division of Toxicology, CSIR-Central Drug Research Institute, Lucknow, India.
4
Laboratory of Pharmacology, Department of Pharmacology, Gauhati Medical College, Guwahati, India.

Abstract

Breast cancer (BC) is the second most common cause of cancer deaths. Triple-negative breast cancer (TNBC) does not show immunohistochemical expression of oestrogen receptors, progesterone receptors or HER2. At present, no suitable treatment option is available for patients with TNBC. This dearth of effective conventional therapies for the treatment of advanced stage breast cancer has provoked the development of novel strategies for the management of patients with TNBC. This review presents recent information associated with different therapeutic options for the treatment of TNBC focusing on promising targets such as the Notch signalling, Wnt/β-catenin and Hedgehog pathways, in addition to EGFR, PARP1, mTOR, TGF-β and angiogenesis inhibitors.

PMID:
26040571
PMCID:
PMC4556464
DOI:
10.1111/bph.13211
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center